A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer

Paola Gazzaniga, Angela Gradilone, Ettore De Berardinis, Alessandro Sciarra, Cristiano Cristini, Giuseppe Naso, Franco Di Silverio, Luigi Frati, Anna Maria Aglianò

Research output: Contribution to journalArticlepeer-review


OBJECTIVE To describe the design of a new chemosensitivity assay based on the expression of genes involved in the resistance to standard intravesical regimens, to allow individualization of therapy for high-risk non-muscle-invasive bladder cancer. PATIENTS AND METHODS To date, 35 patients with high-risk no-nmuscle-invasive bladder cancer have been enrolled, all candidates for transurethral resection of the bladder (TURB) followed by intravesical treatment. The intravesical regimen was chosen according to the risk profile of each patient. All patients were evaluated by cystoscopy 3 and 6 months after TURB. According to the molecular characterization of each tumour, our team of molecular oncologists determined for each patient a molecular profile of chemosensitivity to BCG, mitomycin c, anthracyclines and gemcitabine. This profile was then correlated to the response to intravesical therapy 6 months after TURB. RESULTS This chemosensitivity test was able to predict response to treatment in 96% of patients. The assay is easy to perform, inexpensive and quick. CONCLUSION Our results, although preliminary, are encouraging for the future of an individualized therapeutic approach, with the aim to provide a higher treatment success rate while sparing patients unnecessary toxicity from drugs that are not suited for their tumours.

Original languageEnglish
Pages (from-to)184-188
Number of pages5
JournalBJU International
Issue number2
Publication statusPublished - Jul 2009


  • Chemosensitivity test
  • Drug resistance
  • Intravesical therapy
  • Non-muscle-invasive bladder cancer

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer'. Together they form a unique fingerprint.

Cite this